VBL Therapeutics: Oppenheimer Healthcare Conference (VBL Therapeutics) - Dec 12, 2014 - "Phase 2 sub-study of VB-201 in vascular inflammation"; "Primary endpont Met: ~13% reduction from baseline in the high dose group (p=0.04)"; "Dose-response pattern observed"; "18.5% reduction of inflammation on top of statin therapy"; "Higher VB-201 trough levels were associated with a better response (>20% in the highest dose range)"; "VB-201 therapy reduced vascular inflammation in patients with psoriasis and cardiovascular risk factors"
P2 data • Immunology • Psoriasis
|